Aspirin-exacerbated respiratory disease: Update on medical management

Aspirin-exacerbated respiratory disease (AERD) is frequently diagnosed in patients with severe type 2 airway inflammation presenting with nasal polyps and severe asthma. It has been associated with a recalcitrant course with high medical and surgical requirements. The advent of recent biological and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrew A. White, Katharine Woessner, Ronald Simon
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2020
Materias:	Aspirin-exacerbated respiratory disease Samter syndrome Aspirin intolerant asthma Nasal polyposis Severe asthma Otorhinolaryngology RF1-547 Surgery RD1-811
Acceso en línea:	https://doaj.org/article/73ca00d87fff4b348cd6858680fce3b7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:73ca00d87fff4b348cd6858680fce3b7
record_format	dspace
spelling	oai:doaj.org-article:73ca00d87fff4b348cd6858680fce3b72021-12-02T14:22:06ZAspirin-exacerbated respiratory disease: Update on medical management2095-881110.1016/j.wjorl.2020.07.009https://doaj.org/article/73ca00d87fff4b348cd6858680fce3b72020-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095881120301384https://doaj.org/toc/2095-8811Aspirin-exacerbated respiratory disease (AERD) is frequently diagnosed in patients with severe type 2 airway inflammation presenting with nasal polyps and severe asthma. It has been associated with a recalcitrant course with high medical and surgical requirements. The advent of recent biological and other targeted treatments show promise in the medical management of patient with AERD. The goal of complete disease control where patients no longer require recurrent surgical procedures, systemic corticosteroid exposure and may live with a stable and relatively normal quality of life is now within reach. Further work is necessary to identify biomarkers predictive of treatment response.Andrew A. WhiteKatharine WoessnerRonald SimonKeAi Communications Co., Ltd.articleAspirin-exacerbated respiratory diseaseSamter syndromeAspirin intolerant asthmaNasal polyposisSevere asthmaOtorhinolaryngologyRF1-547SurgeryRD1-811ENWorld Journal of Otorhinolaryngology-Head and Neck Surgery, Vol 6, Iss 4, Pp 241-247 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Aspirin-exacerbated respiratory disease Samter syndrome Aspirin intolerant asthma Nasal polyposis Severe asthma Otorhinolaryngology RF1-547 Surgery RD1-811
spellingShingle	Aspirin-exacerbated respiratory disease Samter syndrome Aspirin intolerant asthma Nasal polyposis Severe asthma Otorhinolaryngology RF1-547 Surgery RD1-811 Andrew A. White Katharine Woessner Ronald Simon Aspirin-exacerbated respiratory disease: Update on medical management
description	Aspirin-exacerbated respiratory disease (AERD) is frequently diagnosed in patients with severe type 2 airway inflammation presenting with nasal polyps and severe asthma. It has been associated with a recalcitrant course with high medical and surgical requirements. The advent of recent biological and other targeted treatments show promise in the medical management of patient with AERD. The goal of complete disease control where patients no longer require recurrent surgical procedures, systemic corticosteroid exposure and may live with a stable and relatively normal quality of life is now within reach. Further work is necessary to identify biomarkers predictive of treatment response.
format	article
author	Andrew A. White Katharine Woessner Ronald Simon
author_facet	Andrew A. White Katharine Woessner Ronald Simon
author_sort	Andrew A. White
title	Aspirin-exacerbated respiratory disease: Update on medical management
title_short	Aspirin-exacerbated respiratory disease: Update on medical management
title_full	Aspirin-exacerbated respiratory disease: Update on medical management
title_fullStr	Aspirin-exacerbated respiratory disease: Update on medical management
title_full_unstemmed	Aspirin-exacerbated respiratory disease: Update on medical management
title_sort	aspirin-exacerbated respiratory disease: update on medical management
publisher	KeAi Communications Co., Ltd.
publishDate	2020
url	https://doaj.org/article/73ca00d87fff4b348cd6858680fce3b7
work_keys_str_mv	AT andrewawhite aspirinexacerbatedrespiratorydiseaseupdateonmedicalmanagement AT katharinewoessner aspirinexacerbatedrespiratorydiseaseupdateonmedicalmanagement AT ronaldsimon aspirinexacerbatedrespiratorydiseaseupdateonmedicalmanagement
_version_	1718391494612615168

Aspirin-exacerbated respiratory disease: Update on medical management

Ejemplares similares